| Compound Code | KAT-5HT-DA-01 |
| Pharmacological Tag | Dual monoaminergic anorectic |
| Structural Class | Fenfluramine: substituted phenethylamine Phentermine: α-methylated amphetamine |
| Mechanism (Putative) | Fenfluramine: → SERT substrate → serotonin efflux → 5-HT2C receptor agonism → satiety signaling → VMAT2 interaction → vesicular depletion Phentermine: → DAT/NET inhibition → Dopaminergic elevation → hunger suppression → Sympathomimetic excitation |
| Functional Role | Serotonin-mediated appetite suppression Dopamine-driven vigilance and metabolic activation Anorectic synergy: satiety + stimulation |
| Structural Analogues | Dexfenfluramine Methamphetamine MDMA Sibutramine Mazindol |
| Predicted Onset | Oral: 20–40 min (combined) |
| Predicted Duration | 6–8 hours (dose-dependent) |
| Affinity Profile | SERT >>> DAT > NET Minimal affinity for adrenergic or histaminergic targets |
| Computational Predictions | CNS Activity: High BBB Penetration: Positive (both components) 5-HT2B Agonism (Fenfluramine): Present → valvular risk Mutagenicity: Low Neurotoxicity Risk: High (monoamine depletion at supratherapeutic doses) Metabolism: → Fenfluramine → norfenfluramine (active) → Phentermine → hydroxylation + N-dealkylation |
| Interpretation | A dual molecule program designed to cancel appetite by both inducing satiety and suppressing seeking behavior. Strategically banned, pharmacologically instructive. Fen-Phen is a historic neurochemical system: metabolic totalitarianism via neurotransmitter orthodoxy. Proof of concept: desire can be disabled. |